ReViral to Present Data Showing Absence of Clinical Resistance in Volunteers Infected with RSV then Treated with Sisunatovir (RV521) May 14, 2019 by ReViral Ltd Read More
ReViral Announces Grant of Key US Composition of Matter Patent For Their Respiratory Syncytial Virus inhibitor programme Apr 8, 2019 by ReViral Ltd Read More
ReViral to present at Microbiology Society Annual Conference 2019 Apr 5, 2019 by ReViral Ltd Read More
ReViral Ltd Appoints Seth Hetherington as Chief Medical Officer as it Prepares its Lead RSV Candidate to Enter Pediatric Phase IIa Clinical Trials Feb 26, 2019 by ReViral Ltd Read More
